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6784 | Chem. Sci., 2017, 8, 6784–6798guided discovery of antimicrobial
bridged bicyclic peptides against Pseudomonas
aeruginosa and its bioﬁlms†
Ivan Di Bonaventura,a Xian Jin,a Ricardo Visini,a Daniel Probst,a Sacha Javor,a
Bee-Ha Gan,a Gae¨lle Michaud,a Antonino Natalello, b Silvia Maria Doglia,b
Thilo Ko¨hler,c Christian van Delden,c Achim Stocker,a Tamis Darbrea
and Jean-Louis Reymond *a
Herein we report the discovery of antimicrobial bridged bicyclic peptides (AMBPs) active against
Pseudomonas aeruginosa, a highly problematic Gram negative bacterium in the hospital environment.
Two of these AMBPs show strong bioﬁlm inhibition and dispersal activity and enhance the activity of
polymyxin, currently a last resort antibiotic against which resistance is emerging. To discover our AMBPs
we used the concept of chemical space, which is well known in the area of small molecule drug
discovery, to deﬁne a small number of test compounds for synthesis and experimental evaluation. Our
chemical space was calculated using 2DP, a new topological shape and pharmacophore ﬁngerprint for
peptides. This method provides a general strategy to search for bioactive peptides with unusual
topologies and expand the structural diversity of peptide-based drugs.Introduction
The emergence of multi-antibiotic resistance in pathogenic
bacteria represents one of the major public health threats today,
calling for new approaches to develop antibiotics, in particular
against Gram-negative bacteria such as Pseudomonas aeruginosa
and Acinetobacter baumannii.1–4 One promising approach consists
in searching for new antimicrobial peptides (AMPs), a versatile
class of antibiotics produced by animals, plants and microor-
ganisms. AMPs act by various mechanisms such as perturbing the
cytoplasmic bacterial membrane, interacting with intracellular
targets and modulating the host immune system.5–12
Besides linear peptides, a variety of cyclic, polycyclic and
lasso topologies also occur in AMPs.13–26 The importance of such
unusual topologies is highlighted by polymyxin (Pmx), a lipi-
dated branched cyclic decapeptide currently used as a last resort
antibiotic against Gram negative multidrug resistant (MDR)
pathogens, but against which resistance is appearing.27
Following on reports of antimicrobial activities in polycationic
dendrimers including peptides,28–30 we recently screened, University of Bern, Freiestrasse 3, 3012
d@dcb.unibe.ch
ces, University of Milano-Bicocca, Piazza
ar Medicine, University of Geneva, and
spital of Geneva, Geneva, Switzerland
(ESI) available: Characterization of all
haracterization of all compounds. Seecombinatorial libraries of peptide dendrimers prepared by
solid-phase peptide synthesis (SPPS)31–33 using an antimicrobial
activity assay originally developed to search for new analogs of
cyclic AMPs,34 and discovered antimicrobial peptide den-
drimers (AMPDs) interacting with the bacterial membrane,35,36
which we later optimized by sequence design to AMPDs (e.g.
G3KL, Fig. 1) with potent activities against various strains of P.
aeruginosa and A. baumannii.37,38 Inspired by the remarkable
serum stability of our peptide dendrimers, we later expanded
our exploration of multi-branched synthetic peptides by SPPS to
bridged bicyclic peptides (e.g. BCP27c, Fig. 1).39–41 These bicyclic
peptides showed comparable serum stabilities to our peptide
dendrimers but better dened structures and favourable prop-
erties as drug scaﬀolds.42 Herein we report the identication of
antimicrobial bridged bicyclic peptides (AMBPs) active against
Gram negative P. aeruginosa and its biolms as the rst example
of applying our bicyclic peptides to a specic biological activity.
Because the synthesis of bridged bicyclic peptides requires
purication of an intermediate prior to cyclization, a combina-
torial chemistry and high-throughput screening approach was
not readily applicable here as a tool for discovery.43–45 As an
alternative compatible with the synthesis of only a few well-
characterized compounds we used the idea of chemical space
as a guide to select test compounds. A chemical space is a multi-
dimensional virtual space in which dimensions correspond to
diﬀerent numerical descriptors of molecular structure, which
together form a multi-dimensional feature vector, or nger-
print. Chemical space is a well-known concept in the area of
small molecule drug discovery, where it is used to select smallThis journal is © The Royal Society of Chemistry 2017
Fig. 1 Structures of AMPD G3KL (ref. 37), bicyclic peptide BCP27c
(calmodulin binder, ref. 42), and AMBPs 27b and 62b identiﬁed in this
study. The peptides are shownwith amino acids in one letter codewith
branching residues in italics and peptide bonds as arrows in C / N
direction. Z ¼ branching g-homoglutamic acid (formed by ClAc liga-
tion of cysteine).
Scheme 1 Synthesis and structure of AMBPs containing a double
thioether bridge. X1–X13 are variable L-amino acids or a deletion.
Conditions: (a) (i) piperidine/DMF 1 : 4, (ii) FmocAAOH, oxyma/DIC,
DMF or (ClCH2CO)2O, CH2Cl2; (b) TFA/TIS/DODT/H2O
94 : 2.5 : 2.5 : 1, v/v/v/v; (c) H2O/MeCN (50 : 50, v/v), KI (1 eq.), DIEA (5
eq.); (d) DCM/TES/TFA (96 : 3 : 1, v/v/v); (e) Pd(PPh3)4 (0.25 eq.), DCM,
phenylsilane (25 eq.).
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View Article Onlineyet diverse subsets from large compound collections for exper-
imental assays, as well as to optimize initial hits by searching
for nearest neighbours.46–50 However it has not been used
previously to design peptides.
As detailed below, using a chemical space encoding molec-
ular shapes and pharmacophores to describe bicyclic peptides
enabled us to logically explore their diversity using only a small
number of test compounds, and later to optimize initial hits by
focusing on nearest neighbours. This chemical space guided
search led to the discovery of AMBP 27b, which we further
optimized to its lipidated analog 62b acting on P. aeruginosa
including several MDR clinical isolates (Fig. 1). We furthermore
identied the related AMBPs 29b and 36b showing a potent
anti-biolm activity comparable to the recently reported D-
enantiomeric peptide DJK5 (Scheme 1, Table 1).51 Our approach
signicantly extends previously reported computer-aided
design methods for peptides, which are all based on extrapo-
lating from the sequences of known linear AMPs to design new
linear sequences,52–54 and might be generally useful to exploreThis journal is © The Royal Society of Chemistry 2017unusual peptide topologies and expand the structural diversity
of peptide-based drugs.Results and discussion
Fingerprint design and validation
We focused on the membrane disrupting properties of AMPs,
which mostly depend on the number and relative position of
cationic and hydrophobic residues in a peptide sequence. We
envisioned that this information might be encoded as a topo-
logical atom pair ngerprint, a well-known method to describe
shapes and pharmacophores in small molecules.55–59
Our starting point was our recently reported 3DP ngerprint
encoding the 3D-shape and pharmacophores of proteins from
their experimental 3D-structure, which we used to create a web-
based interactive map of the Protein Data Bank (PDB).60 The
3DP ngerprint comprises four atom categories: all atoms,
cationic, anionic, and hydrophobic atoms. Distances between
atoms are measured from the 3D-coordinates of the atoms in
the experimental X-ray structures. To compute the ngerprint,
each atom pair is converted to a Gaussian centered around the
atom-pair distance. The sum of all Gaussians is then divided by
HAC1.5 (HAC ¼ heavy atom count, all non-hydrogen atoms) to
reduce the dependency to molecule size, and sampled at 34
distances spanning the range 1.45–400 A˚ exponentially.
To obtain the corresponding atom-pair ngerprint 2DP
based on topological distances, we used the formula for 3DP,
but assigned all atoms to the a-carbon atom of their parentChem. Sci., 2017, 8, 6784–6798 | 6785
Table 1 Synthesis and bioactivity of selected AMBPsa
No. Sequencea Hb +c MS calc./obs. [M] MIC BR 151d MIC PAO1d MBICe Dispersalf MHCg
1a 2K(1)KZ1KLZ2L 2 2 914.19/914.19 >256 >256
1b 1K(2)KZ1KLZ2L 2 2 914.19/914.19 128 >256
11a L1LK(L2L)KLKZ2KKLZ1K 6 5 1750.11/1750.11 64 >256
11b L1LK(L2L)KLKZ1KKLZ2K 6 5 1750.11/1750.11 16 >256
13a K2LLK(K1LL)KLZ1KKLZ2 6 5 1750.11/1750.11 16 >256
13b K1LLK(K2LL)KLZ1KKLZ2 6 5 1750.11/1750.11 16 >256
15 L12KK(L12K)KLKZ21LLKZ12L 6 5 1750.11/1750.11 16 >256
19 K12LKK(K12LK)LLLZ21KLKZ12L 7 6 1991.29/1991.29 8 >256
20 12LLKK(L12LK)LLLZ21KLKZ12L 9 4 1961.27/1961.27 4 128 32 60%
24 12LLKK(L12LK)KLKZ21LLKZ12L 8 5 1976.28/1976.28 4 128 16 50%
26a 1KLLK(K2LL)KLLZ2KLKZ1K 7 6 1991.29/1991.30 32 >256 125
26b 1KLLK(K2LL)KLLZ1KLKZ2K 7 6 1991.29/1991.30 1 128 32 36% 250
27a 2KLKK(K1LK)KLLZ1LLLZ2K 7 6 1991.29/1991.30 32 256 1000
27b 1KLKK(K2LK)KLLZ1LLLZ2K 7 6 1991.29/1991.30 1 32 32 12% 2000
29a 2KLLK(K1LL)KLLZ1KKKZ2L 7 6 1991.29/1991.29 16 >256 32 0% 2000
29b 1KLLK(K2LL)KLLZ1KKKZ2L 7 6 1991.29/1991.29 2 256 8 100% 2000
36a 2KLKK(K1LK)KLLZ1LLKZ2K 6 7 2006.30/2006.30 32 >256 >32 0% 2000
36b 1KLKK(K2LK)KLLZ1LLKZ2K 6 7 2006.30/2006.30 16 64 8 100% 2000
37a 2KLKK(K1LK)KLLZ1KLKZ2L 6 7 2006.30/2006.30 32 >256 16 30%
37b 1KLKK(K2LK)KLLZ1KLKZ2L 6 7 2006.30/2006.30 32 256 16 100%
39a 1LLKK(L2LK)KKLZ2LLLZ1K 8 5 1976.28/1976.28 16 128
39b 2LLKK(L1LK)KKLZ2LLLZ1K 8 5 1976.28/1976.28 4 64 >32
56a 1KKKK(K2KK)KLLZ2LLLZ1K 5 8 2021.31/2021.31 4 128 >32 0%
56b 2KKKK(K1KK)KLLZ2LLLZ1K 5 8 2021.31/2022.31 2 32 32 75%
58a 2KFKK(K1FK)KFFZ1FFFZ2K 7 6 2229.18/2230.18 2 >256 32 80%
58b 1KFKK(K2FK)KFFZ1FFFZ2K 7 6 2229.18/2229.18 2 >256 32 0%
59 12KWKK(K12WK)KWWZ21WWWZ12K 7 6 2502.25/2502.25 1 64 32 0%
60a 2BLBK(B1LB)BLLZ1LLLZ2B 7 6 1823.10/1824.10 4 64 >32 0%
60b 1BLBK(B2LB)BLLZ1LLLZ2B 7 6 1823.10/1823.10 4 64 >32 0%
61 12RLRK(R21LR)RLLZ21LLLZ12R 7 6 2160.62/2160.52h 1 64 >32 0%
62a 2KLKK(K1LK)KLLZ1LLLZ2KK(C10) 8 6 2273.52/2273.52 4 32 128 15% 125
62b 1KLKK(K2LK)KLLZ1LLLZ2KK(C10) 8 6 2273.52/2273.52 1 16–8 128 0% 125
Pmx Polymyxin B 4 5 1301.56/1301.56 4 2 16 100% 2000
+1 mg mL1 29b 1.5 100%i
+0.5 mg mL1 36b 1.5 100%i
DJK5 Vqwrairvrvir 7 4 1549.47/1549.47 16 4 100% 2000
a Sequences use standard one-letter codes for amino acids, K ¼ branching lysine, the peptide extended on the side chain is in parentheses, Z ¼ g-
thia-homoglutamic acid (formed by ClAc ligation of cysteine), 1 and 2 indicate cyclization points using the SMILES formalism, B ¼ diaminobutyric
acid. All C-termini are carboxamides. b H¼ number of hydrophobic residues. c +¼ number of positive charges. d Minimal inhibitory concentration
in mg mL1 in Mu¨ller–Hinton (MH)-broth. e Minimal biolm inhibitory conc. in mg mL1. f Dispersal of preformed biolm at 32 mg mL1. MIC,
MBIC and dispersal determinations were performed in independent triplicates with at least two experiments giving the same value. g Minimal
hemolytic concentration in mg mL1 on human red blood cells (hRBC). MHC determinations were performed in duplicate and averaged. h In
this case [M + H]+ is observed together with TFA adducts, see ESI. i Measured with 8 mg mL1 of 29b or 36b in the presence of 1.5 mg mL1 of
Pmx, FIC (fractional inhibitory concentration):63 36b + Pmx ¼ 0.155 (MBIC), 0.34 (dispersal), 29b + Pmx ¼ 0.218 (MBIC), 0.34 (dispersal). Empty
entries were not determined.
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View Article Onlineresidue and counted distances between pairs of a-carbon atoms
in bonds along the shortest path as determined from the 2D-
structure of the peptides. The 2DP ngerprint comprised 136
values and dened a 136-dimensional chemical space, here
called 2DP-space (Fig. 2a). Since 2DP used topological distances
the ngerprint and its associated chemical space were well
suited to explore peptides whose 3D-structure is yet unknown or
poorly dened due to conformational exibility.
We performed three benchmarking studies to test the
performance 2DP for virtual screening. Specically, we tested if6786 | Chem. Sci., 2017, 8, 6784–6798nearest neighbour searches in 2DP-space, using the city-block
distance as similarity measure,61 could recover close analogs
of linear peptides.
First, we extracted 2073 peptides up to 50 residues from the
PDB, computed their 3DP from their X-ray structures and their
2DP from their sequences, respectively, and tested the recovery of
3DP-nearest neighbours of each peptide among a subset of
peptides of similar size using 2DP similarity. The performance of
each of the 2073 recoveries was quantied by the area under the
receiver operating characteristic curve (AUROC). An AUROC > 80%This journal is © The Royal Society of Chemistry 2017
Fig. 2 Design and benchmarking study of the 2DP ﬁngerprint. (a)
Equation for the calculation of 2DP entries for each atom category. (b)
Performance of 2DP nearest neighbor searches for recovering various
peptide types. Frequency histogram of AUROC values for recovering
up to 100 3DP-nearest neighbours of each of the 2073 peptides up to
50 residues in the Protein Data Bank from all other entries within10%
size of each query (blue curve), recovering 309 AMP sequences from
50 AMP sequences among 8815 decoys sequences in the UniProt
databank (all limited to 50 residues, red curve), and recovering the
closest BLAST analogs (with bit score > 19, 110-285 BLAST analogs) of
50 diﬀerent 13-mer peptides from 8000 randomly scrambled peptide
sequences of the query peptide (green curve).
Edge Article Chemical Science
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
3 
Ju
ly
 2
01
7.
 D
ow
nl
oa
de
d 
on
 1
8/
12
/2
01
7 
13
:2
5:
27
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Onlineindicative of good recovery characteristics78 was observed with
over 70% of the peptides (Fig. 2b, blue line). This showed that 2DP
partially perceived the 3D-shape and pharmacophore of peptides
despite of only reading information from their 2D-structure.
Second, 2DP similarity searches were also performed to
recover AMPs from decoys among linear peptides up to 50
residues in the UniProt database.79 The recovery characteristic
were mostly excellent (AUROC > 80%, Fig. 2b red line), sug-
gesting that 2DP was well suited to search for AMPs. Finally,
2DP was tested for recovering BLAST sequence analogs from
scrambled sequences of short 13-mer peptides. Here also 2DP
performed acceptably well (AUROC > 70%, Fig. 2b green line),
showing that our ngerprint partly encoded peptide sequences
even without direct encoding of amino acid residues.
Taken together, these retrospective analyses showed that
2DP-space oﬀered a meaningful representation of linear
peptides in terms of molecular shape, antimicrobial activities
and sequences. In the absence of validation datasets for topo-
logically diverse peptides, the above data with linear peptides
combined with the similarity of 2DP with atom-pair ngerprints
for encoding the shape and pharmacophores of small mole-
cules, which are topologically diverse, convinced us to apply
2DP to explore bridged bicyclic peptides.Fig. 3 Chemical space analysis of bridged bicyclic peptides. (a) Distri-
bution of pairwise 2DP-distances between compounds in the entire
library and its three subsets. Distances are calculated as city-block
distance in the 136-D 2DP space. (b)–(e) Color-coded images of the
various sets of bicyclic peptides in the (PC1, PC2, PC3)-space obtained by
PCA of 2DP-space. Variance covered: PC1 (30%), PC2 (16%), PC3 (11%).Synthesis design and 2DP-space analysis
We used 2DP-space to analyze a family of bridged bicyclic
peptides resulting from a double chloroacetyl thioether (ClAc)
ligation62 of a rst generation peptide dendrimer containing
two cysteine residues in its stem. The two possible isomersThis journal is © The Royal Society of Chemistry 2017formed by cyclization were accessible by SPPS either as mixture,
or as single isomers using an orthogonal protecting group
strategy (Scheme 1).
Using six possible residues typical for membrane active
AMPs (lysine, arginine, diaminobutyric acid, leucine, phenyl-
alanine, tryptophan) or a deletion at the 10 variable positions
dened 243 235 706 possible bicyclic peptides. Focusing on
lysine and leucine reduced the enumeration to only 20 250
peptides (subset 1), 6230 of which had a ratio Lys/Leu z 1
favorable for antimicrobial activity (subset 2).37 Subset 2 was
sampled by centroid clustering to select 19 pairs of bicyclic
peptide isomers between 8 and 16 residues in size for synthesis
(subset 3). The three subsets spanned 2DP-diversity as broadly
as the entire library as measured by a histogram of pairwise
2DP-distances (Fig. 3a). Nevertheless, visualization of the
diﬀerent subsets in the principal component analysis volume
(PC1, PC2, PC3) color-coded by charge, molecular size andChem. Sci., 2017, 8, 6784–6798 | 6787
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View Article Onlinehydrophobic atoms showed that the two subsets with Lys/Leuz
1 covered a somewhat more restricted region of 2DP-space
compared with the complete library (Fig. 3b–e).Discovery of AMBPs and biolm inhibitors
The synthesis of the bicyclic peptides in subset 3 was performed
by SPPS, purication of the chloroacetylated peptide dendrimer
intermediate, double cyclization in solution and nally puri-
cation of the bicyclic peptide by preparative HPLC (Scheme 1,
le). The syntheses yielded 28 bicyclic peptides as pure isomers
separated by preparative HPLC, and 5 bicyclic peptides as
inseparable mixtures of two isomers (1–19, Table S1,† active
AMPDs shown in Table 1).
While this initial series was inactive against P. aeruginosa
(PAO1), we found several active bicyclic peptides against Bacillus
subtilis (BR 151), a Gram-positive bacterium oen sensitive to
membrane disrupting compounds. Although an antimicrobial
eﬀect was already observable in 1b, the smallest bicyclic peptide
in the series, activity generally increased with size and was
strongly sequence and partly isomer dependent, with 19
showing the best activity in the series.
Assuming that AMBP 19 marked a bioactive region in 2DP-
space we selected 100 of its nearest neighbours in 2DP space
from the 20 250 bicyclic peptides in subset 1 (Fig. 3). We then
clustered these nearest neighbours in ve groups and cherry-
picked 3 to 4 sequences from each group for synthesis and
experimental evaluation. These analogs had the same size as 19Fig. 4 Serum stability and membrane disruptive properties of AMBPs. (a
37 C. The decrease of the peptide peak was followed by LC/MS. (b) F
intensity upon treatment of ﬂuorescein loaded PG vesicles with 5 mg mL
cells treated with AMPs.
6788 | Chem. Sci., 2017, 8, 6784–6798but diﬀerent sequences and ratios of leucine to lysine (20–38,
Table S2,† the most active AMPDs are shown in Table 1).
Synthesis and testing revealed additional hits against B. subtilis
as well as 26b, 27b and 36b as the rst AMBPs with signicant
activity against P. aeruginosa. Strikingly activity was systemati-
cally occurring in isomer b.
A third round of virtual screening, synthesis and testing of 2DP
nearest neighbors of 27b (28 pure isomers and 5 isomeric
mixtures, 39–57, Table S3,† active AMBPs shown in Table 1) did
not yield improved activities, suggesting that 27b marked a local
activity optimum. We therefore turned to designing specic
analogs for further activity improvements. Analogs of 27b
featuring exhaustive Leu/ Phe (58b), Leu/ Trp (59), Lys/Dab
(60b) or Lys/ Arg (61) replacements, which in principle probed
compounds belonging to the larger virtual library of 243 M
structures (Fig. 3a and b), were less active. On the other hand
adding a side-chain decanoylated lysine at the C-terminus as
a hydrophobic extension similar to that found in polymyxin gave
AMBP 62b with increased activity against P. aeruginosa PAO1
(Table 1). AMBP 62b also showed moderate activity against several
multidrug resistant P. aeruginosa clinical isolates, and Acineto-
bacter baumannii (Table S4†).
In view of the importance of biolms in bacterial infections we
tested all active AMBPs against P. aeruginosa biolms using
a protocol used earlier in our laboratory to investigate glycopep-
tide dendrimer biolm inhibitors.64–66 These assays identied 29b
and 36b as two particularly active AMBPs for biolm inhibition) Stability assay in human serum. AMBPs were incubated at 200 mM at
luorescein leakage assay from PG vesicles with 62b. (c) Fluorescence
1, t ¼ 150 s, for the indicated AMBPs. (d) TEM images of P. aeruginosa
This journal is © The Royal Society of Chemistry 2017
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View Article Onlineand dispersal. Their activity was comparable to that of the recently
reported linear all-D peptide biolm inhibitor DJK5.51 As for DJK5,
29b and 36b were also less active against planctonic P. aeruginosa
than against its biolms. Remarkably 29b and 36b showed
a synergistic eﬀect with polymyxin on biolm inhibition and
dispersal (Table 1 and Fig. S4–S18†).Extended activity proling and membrane disruptive activity
The identied AMBPs were only moderately hemolytic (Table 1),
and were generally resistant to serum degradation, presumably
due to their branched cyclic structure limiting access of serum
proteases to peptide bonds (Fig. 4a). Interestingly the more
active isomers b were generally more resistant to serum degra-
dation than isomers a. AMBP 27b eﬃciently released uores-
cein from large unilamellar vesicles (LUVs) consisting of
anionic phosphatidyl glycerol (PG), which mimic the bacterial
membrane. The eﬀect was stronger than with its less active
isomer 27a, a trend also observed with the pair 26b/26a and 62b/
62a (Fig. 4b and c and S19–S21†). Membrane perturbations were
also visible in transmission electron microscopy (TEM) images
of bacterial cells exposed to 27b or 62b showing the formation
of multiple membrane protrusions similar to those observed
with polymyxin (Fig. 4d, S22 and S23†).67 By contrast biolmFig. 5 X-ray crystallography and molecular dynamics of AMBPs. (a) Overv
3.5 A˚) of the X-ray structure the 63a$LecB complex (PDB code 518M). Eac
visible ligands are shown in CPK models. Only one of the four fucose bin
peptide ligand, which is immobilized though contacts with other LecB u
written in black. LecB residues engaging in direct contact with the AMB
shown in the upper ﬁgure. (b) Similar representation of 63b$LecB (PDB co
of the fucosylated analogs 63a/b and for 27a/b from MD simulation. (d)
100 ns of MD at 300 K after simulated annealing. Blue ¼ Lys, brown ¼ L
This journal is © The Royal Society of Chemistry 2017inhibitors 29b and 36b only weakly disrupted PG LUVs, sug-
gesting that these might act by a diﬀerent mechanism.Structural studies
We performed an isomer selective synthesis of 1a, 1b, 27a, and
27b using diﬀerentially protected cysteine building blocks and
an 3-alloc protected lysine as branching point allowing
sequential growth and cyclization of each branch independently
(Scheme 1, right, see also Scheme S1† for details). These
selective syntheses showed that for isomer b – in both cases the
more active isomer eluting second during HPLC purication –
the large dodecapeptide macrocycle runs through the 3-amino
group of the branching lysine and is therefore longer than in
isomer a (Scheme 1).
We then turned to crystallography to gain additional struc-
tural insights into our AMBPs. While direct crystallization
attempts with several AMBPs failed, we obtained the X-ray
crystal structures of the smallest AMBPs 1a and 1b through
their fucosylated derivatives of 63a and 63b in complex with P.
aeruginosa lectin LecB. In 63a/b the sequence of 1a/b has been
extended by an additional lysine residue at the C-terminus,
whose side-chain is acylated with a-L-fucosylacetic acid. This
fucoside appendage is used to anchor the peptide to the lectin,
which crystallizes readily, a principle generally useful to accessiew (upper) and electron density with contacts (lower, distance cut-oﬀ
h LecB subunit is shown in ribbon diagramwith a diﬀerent color and the
ding sites of the lectin tetramer is occupied by a fully resolved bicyclic
nits in the crystal lattice. In the lower image residues of the AMBP are
P are drawn and labeled in the color of the corresponding subunit as
de 518X). (c) Structural model of the backbone for 1a/b from X-ray data
11 superimposed structures of the complete AMBP 27a/b from the last
eu. See also ESI Table S6, S7, Fig. S26 and S27.†
Chem. Sci., 2017, 8, 6784–6798 | 6789
Fig. 6 FTIR data with 27a/b, showing the Fourier self-deconvoluted
spectra (left) and the second derivative (right). Bicyclic peptides were
dissolved at a ﬁnal concentration of 6 mg mL1 in D2O based PBS (aq.
10 mM phosphate, 150 mM NaCl, pH 7.4) in the presence of 0% (blue
lines), 50% (green lines), and 90% (red lines) of TFE at 25 C.
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View Article Onlinestructural information on molecules otherwise diﬃcult to
crystallize.66,68,69 Here the crystal structures showed well dened
peptide macrocycles for both AMBPs, which were immobilized
in the crystal lattice not only via their anchoring fucosyl group,
but also through several hydrogen bonds between the peptide
backbone and the lectin (Table S5,† Fig. 5a and b). On the other
hand, the amino acid side chains were mostly not visible indi-
cating conformational exibility. For both isomers the dihedral
angles of the peptide backbone resided in allowed regions of the
Ramachandran plot suggesting minimal strain (Fig. S24†),
although a cis-peptide bond was present in the case of 63a.
These structures also conrmed the isomer assignment derived
from the selective synthesis. An additional X-ray structure was
obtained for a LecB complex with 64a, an analog of 63a with
a sequence designed to facilitate crystallization, and for which
a well-resolved electron density was obtained including all
residue side-chains, providing additional support for the
structural assignment (PDB code 5NGQ, Table S5 and
Fig. S25†).
LecB complexes with 65a or 65b, the fucosylated analogs of
27a and 27b, also gave well-diﬀracting crystals, however without
observable electron densities for their ligand except for the
anchoring fucosyl group, probably because these AMBP did not
engage in immobilizing contacts with the lectin and retained an
important conformational exibility in the crystal lattice. We
therefore performed molecular dynamics (MD) simulations in
explicit water using the GROMACSmolecular modeling package
to gain a structural insight.70
A starting conformation was generated using the CORINA
soware.71 To access an unbiased set of stable conformations in
solution, the model was rst heated to 450 K to produce 11
snapshots of high energy structures that were progressively
cooled to 300 K in a simulated annealing procedure. The low
energy structures were then clustered and analyzed. These MD
simulations indicated relatively stable and signicantly
diﬀerent backbone geometries for each isomer, which resulted
in signicantly diﬀerent overall structures despite of the exi-
bility of the lysine and leucine side chains (Fig. 5c and d).
In the structural model obtained by MD for 27a/b the
hydrophobic leucine side chains and the positively charged
lysine side chains formed distinct groups, partly as a result of
the peptide sequence, which could be interpreted in terms of an
amphiphilic structure that might explain membrane disruptive
activity. However these models did not oﬀer a convincing
structural rationale for the stronger activity of b isomers
compared to a isomers.
To gain additional insights we performed Fourier transform
infrared (FTIR) spectroscopy in diﬀerent media to probe
whether the more active isomer 27b might undergo more
pronounced conformational changes than 27a between water
and the membrane environment since such changes are typi-
cally linked to antimicrobial and membrane disruptive activi-
ties of AMPs.5–12 FTIR spectra of 27a and 27b were recorded in
aqueous PBS containing up to 90% triuoroethanol (TFE) to
mimic a transition from the aqueous environment to the
membrane environment. Both isomers behaved similarly and
showed a shi of the broad Amide I0 peak from 1638 cm1 in6790 | Chem. Sci., 2017, 8, 6784–6798aqueous PBS indicative of disordered hydrated a-helices to 1650
cm1 in the presence of TFE characteristic for buried a-helices
(Fig. 6). Similar FTIR data were observed with AMBPs 26a/b and
biolm inhibitor 29a/b (Fig. S28†).
Since our AMBPs cannot fold into an a-helix due to their
bicyclic topology we interpret the FTIR data in terms of
a conformational rearrangement from a hydrated conformation
in water to a more compact state in the membrane environ-
ment. However, the fact that both isomers undergo such
conformational rearrangement to a similar extent implies that
this eﬀect cannot explain their diﬀerent antimicrobial and
vesicle leakage activities. We therefore propose that the stronger
activity of b isomers versus a isomers results from diﬀerences in
structure, as observed in the X-ray and MD studies above, rather
than from diﬀerences in conformational exibilities. Note that
the chromatographic evidence that b isomers elute second and
are therefore slightly more hydrophobic than a isomers
suggests that they might engage in stronger interactions with
the bacterial membrane.Conclusion
In summary, the synthesis and evaluation of only a limited
number of puried products guided by the concept of chemical
space allowed us to discover 27b as the rst AMBP active against
P. aeruginosa. We optimized this AMBP to 62b, a lipidated
analog with increased potency and activity against MDR clinical
isolates. These AMBPs showed the hallmarks of a membrane
disruptive activity. Screening of all active AMBPs for biolm
inhibition additionally led to the discovery of 29b and 36b as
two potent P. aeruginosa biolm inhibitors showing an inter-
esting synergy with polymyxin. These discoveries suggest that
bridged bicyclic peptides might represent a useful new class of
antimicrobial peptides and biolm inhibitors.
To the best of our knowledge the chemical space guided
approach demonstrated here with 2DP, a new shape and
pharmacophore ngerprint inspired by computer-aided drug
design methods for small molecules, is unprecedented for
peptides. This method provides a general strategy to search for
bioactive peptides with bicyclic or other unusual multi-This journal is © The Royal Society of Chemistry 2017
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View Article Onlinebranched topologies unsuitable for combinatorial synthesis
and requiring careful evaluation of individually synthesized and
puried compounds. Such exploratory approaches outside of
standard topologies should help in expanding the structural
diversity of peptide-based drugs. Although the sequences
surveyed here only contain leucine and lysine, our 2DP nger-
print perceives detailed sequence elements (Fig. 2b, BLAST
search) and should therefore be applicable to explore more
diverse amino acid sequences and possibly other types of bio-
logical activities encountered with peptides.Experimental
Cheminformatics
Fingerprint calculation. In 2DP, the topology of a peptide is
encoded in a graph with nodes representing the a-carbon and
edges the bonds between two a-carbons, respectively. An edge's
weight is determined by the number of bonds along said edge.
Nodes store categorical information about the amino acid
residue, namely the number of (1) all non-hydrogen atoms
(HAC), (2) positively charged atoms (PCHRG), (3) negatively
charged atoms (NCHRG) and (4) hydrophobic atoms (HYB) in
the residue. The ngerprint is calculated using an in-house Java
program relying on the Topology Analyzer Plugin provided as
part of the JChem library by ChemAxon, Pvt. Ltd. The nger-
print calculation is implemented by centering a Gaussian
function at the topological atom pair distance dAB, with a stan-
dard deviation of 0.09dAB (9% of the atom pair distance). The
function is sampled at topological distances of 1.45 to 400 (d0¼
1.45, dn+1 ¼ dn  1.18) resulting in 34 bits for each category,
a total of 136 bits. For each of these 136 bits, the values are then
summed across all atom pairs in each of the four categories and
normalized by HAC1.5. Finally, the categories HAC, PCHRG,
NCHRG and HYB were weighted by 1.0, 5.0, 5 and 2 respectively.
Virtual library enumeration. A library of peptide sequences
was generated by exhaustively enumerating all possible bicyclic
peptides (Scheme 1) containing as variable residues X any of the
residues from the set {Phe, Lys, Arg, Dab, Trp, Leu} or a dele-
tion, using an in-house C++ program. There were 121 617 853
bicyclic peptides, each of them giving two possible isomers. For
each enumerated peptide sequence, the 2DP ngerprint was
calculated for each isomer a and b separately.
Visualization. Principal component analysis (PCA) was
applied to the 2DP ngerprints dataset of the 243 235 706
bicyclic peptides (including isomers) to reduce the dimension-
ality from the initial d ¼ 136 to d ¼ 3. The projection matrix
yielded by the PCA of the exhaustively enumerated library was
then also used to create the 3D plots of the subsets “Lys and Leu
only”, “Lys/Leu” and “synthesized” (Fig. 2b–e).Materials and reagents
All reagents were purchased from Fluorochem Ltd, Senn AG, Iris
Biotech Gmbh, Sigma Aldrich, TCI (Tokyo Chemical Company).
Chemicals were used as supplied and solvents were of analytical
grade. Amino acids were used as the following derivatives:
Fmoc-Cys(Trt)-OH, Fmoc-Cys(Mmt)-OH, Fmoc-Leu-OH, Fmoc-This journal is © The Royal Society of Chemistry 2017Lys(Boc)-OH, Fmoc-Lys(Fmoc)-OH, Fmoc-Lys(Alloc)-OH, Fmoc-
Phe-OH, and Fmoc-Trp(Boc)-OH. Rink amide MBHA and Rink
amide AM resins were purchased from Novabiochem, TentaGel
Rink amide resin was purchased from Rapp Polymere. Cyclic
peptide synthesis was performed manually and automatically
by Biotage Initiator + Alstra and CEM Liberty Blue Automated
Microwave Peptide Synthesizer.Analytics
Analytical RP-HPLC was performed with an Ultimate 3000 Rapid
Separation LC-MS System (DAD-3000RS diode array detector)
using an Acclaim RSLC 120 C18 column (2.2 mm, 120 A˚, 3  50
mm, ow 1.2 mL min1) from Dionex. Data recording and pro-
cessing was done with Dionex Chromeleon Management System
Version 6.80 (analytical RP-HPLC). All RP-HPLC were using HPLC-
grade acetonitrile and Milli-Q deionized water. The elution solu-
tions were: A MilliQ deionized water containing 0.05% TFA; D
MilliQ deionized water/acetonitrile (10 : 90, v/v) containing 0.05%
TFA. Preparative RP-HPLC was performed with a Waters auto-
matic Prep LC Controller System containing the four following
modules:Waters 2489 UV/Vis detector,Waters 2545 pump,Waters
Fraction Collector III and Waters 2707 Autosampler. A Dr Maisch
GmbH Reprospher column (C18-DE, 100 30 mm, particle size 5
mm, pore size 100 A˚, ow rate 40 mL min1) was used.
Compounds were detected by UV absorption at 214 nm using
a Waters 248 Tunable Absorbance Detector. Data recording and
processing was performed with Waters ChromScope version 1.40
from Waters Corporation. All RP-HPLC were using HPLC-grade
acetonitrile and Milli-Q deionized water. The elution solutions
were: A MilliQ deionized water containing 0.1% TFA; D MilliQ
deionized water/acetonitrile (10 : 90, v/v) containing 0.1%TFA.MS
spectra, recorded on a Thermo Scientic LTQ OrbitrapXL, were
provided by the MS analytical service of the Department of
Chemistry and Biochemistry at the University of Bern (group PD
Dr Stefan Schu¨rch).Solid-phase peptide synthesis
The peptides were synthesized as mixture of isomers a and b by
SPPS, puried by preparative HPLC, and subsequently sub-
jected to cyclization in solution. The nal products were puri-
ed again, isomers a and b were separated during this second
purication whenever possible.
SPPS was performed either manually in polypropylene
syringes (see below) or by automated SPPS using microwave
synthesizers. The Fmoc-Rink amide resin (0.25 mmol g1, 400
mg) was placed in a 10 mL polypropylene syringe. The resin was
swollen in DCM for 60 min. Aer removal of DCM, the Fmoc
protecting group was removed using a solution of piperidine in
DMF (1 : 4, v/v). Stirring of the reactionmixture at any given step
described below was performed by attaching the closed syringe
to a rotating axis. The following conditions were used:
Removal of the Fmoc protecting group. At each step the Fmoc
protecting group was removed with 8mL of piperidine/DMF (1 : 4,
v/v) for 20 min. Aer ltration the resin was washed with NMP (3
 6 mL), MeOH (3  6 mL) and DCM (3  6 mL).Chem. Sci., 2017, 8, 6784–6798 | 6791
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View Article OnlineCoupling of the Fmoc-protected amino acids before the
branching lysine. 3 eq. of Fmoc-protected amino acid, 3 eq. of
HATU in 7 mL of NMP/DCM (80 : 20, v/v) were added to the
resin. 5 eq. of DIEA were added and the reaction was stirred for
90 min. The resin was then washed with NMP (3 6mL), MeOH
(3  6 mL) and DCM (3  6 mL).
Coupling of the Fmoc-protected amino acids aer the
branching lysine. 6 eq. of Fmoc-protected amino acid, 5 eq. of
HATU in 7 mL of NMP/DCM (80 : 20, v/v) were added to the
resin. 6 eq. of DIEA were added and the reaction was stirred for
120 min. The resin was then washed with NMP (3  6 mL),
MeOH (3  6 mL) and DCM (3  6 mL). The resulting coupling
was checked by TNBS test.
Last Fmoc deprotection and chloroacetylation. Aer the last
amino acid coupling, Fmoc deprotection was performed and
chloroacetylation at the N-temini was performed by adding 10
eq. of chloroacetic anhydride in 8 mL of DCM for 30 min.
Cleavage and purication of the peptide dendrimer. The
cleavage was carried out by treating the resins with 7 mL of
a TFA/DODT/TIS/H2O (94 : 2.5 : 2.5 : 1, v/v/v/v) solution for 3 h.
The peptide solutions were precipitated with 25 mL of TBME,
centrifuged for 10 min at 3500 rpm, resuspended in TBME and
centrifuged again; nally the precipitate was dried under high
vacuum for 60 min. The crude was then dissolved in a water/
acetonitrile mixture and puried by preparative RP-HPLC. The
fractions containing the product (by LC-MS) were then lyophi-
lized. Yields were calculated for the TFA salts of the products.
Cyclization
Bicyclic peptides were synthesized by submitting peptide den-
drimers to high dilution conditions (1 mM) in a mixture of H2O/
MeCN (50 : 50, v/v). The chloroacetylated peptide in H2O/MeCN
was added dropwise to KI (1 eq.) and DIEA (10 eq.) in H2O/
MeCN. The mixture was stirred for 60 min under argon atmo-
sphere. The completion of the reaction was monitored by LC-
MS aer 60 min and lyophilized directly. The products, 2
isomers bicyclic peptides, were then subjected to RP-HPLC
purication with 90 min gradient to achieve separation of the
two isomers and all the fractions were analysed by LC-MS with
a 7.5 min gradient and lyophilized twice. Yields were calculated
for the TFA salts.
Isomer selective synthesis of bicyclic peptides
An orthogonal protecting groups strategy was used to synthesize
selectively compounds 1a, 1b, 27a, 27b (Scheme S1†).
The linear chloroacetylated peptide was rst synthesized
using the standard SPPS procedure described above, but using
Fmoc-Lys(Alloc)-OH at the position of the branching lysine. The
Mmt protecting group was then removed with 8 mL of DCM/
TES/TFA (96 : 3 : 1, v/v/v) for 20 min. Aer ltration the resin
was then washed with NMP (3  6 mL), MeOH (3  6 mL) and
DCM (3  6 mL). The rst thioether ligation was then per-
formed on resin with a mixture of DMF/MeCN (80 : 20, v/v), KI
(5 eq.), DIEA (5 eq.) overnight. Aer ltration, the resin was
washed with NMP (3  6 mL), MeOH (3  6 mL) and DCM (3 
6 mL).6792 | Chem. Sci., 2017, 8, 6784–6798The Alloc group of the branching lysine was then removed as
follows: the polypropylene syringe was equipped with a septum
and dried under vacuum for one hour. It was then swollen in dry
DCM for 20 min under argon. Aer removal of the solvent,
Pd(PPh3)4 (0.25 eq.) was dissolved in 8 mL of dry DCM and
added to the resin under argon. Phenylsilane (25 eq.) was then
added to the resin. The reaction was stirred under argon
bubbling for 45 min (2). The reagents were then removed by
ltration and the resin washed with dry DCM (6 mL, 2  15
min), sodium diethylamino dithiocarboxylate (20 mM in DMF,
6 mL, 10 min) and nally with NMP (3  6 mL), MeOH (3  6
mL) and DCM (3  6 mL).
Aer Alloc deprotection the other branch of the peptide
dendrimer was grown by SPPS, like mentioned above and last
Fmoc deprotection and chloroacetylation were performed like
usual. Cleavage, purication of monocyclic peptide and second
cyclization were performed under standard conditions used
previously.
2K(1)KZ1KLZ2L (1a). 2K(1)KZ1KLZ2L (1a) was obtained as
foamy white solid aer preparative RP-HPLC (24.4 mg, 18.5%).
Analytical RP-HPLC: tR ¼ 2.440 min (A/D 100:0 to 0:100 in
10.00 min, l ¼ 214 nm). MS(ESI+): C40H71N11O9S2 calc./obs.
914.49/914.49 Da [M + H]+.
2K(1)KZ1KLZ2L (1a). 2K(1)KZ1KLZ2L (1a) was also obtained
from the selective synthesis procedure as foamy white solid
aer preparative RP-HPLC (4.2 mg, 3.1%). Analytical RP-HPLC:
tR ¼ 2.540 min (A/D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm).
MS(ESI+): C40H71N11O9S2 calc./obs. 914.49/914.49 Da [M + H]
+.
1K(2)KZ1KLZ2L (1b). 1K(2)KZ1KLZ2L (1b) was obtained as
foamy white solid aer preparative RP-HPLC (7.7 mg, 5.8%).
Analytical RP-HPLC: tR ¼ 2.520 min (A/D 100:0 to 0:100 in
10.00 min, l ¼ 214 nm). MS(ESI+): C40H71N11O9S2 calc./obs.
914.19/914.49 Da [M + H]+.
1K(2)KZ1KLZ2L (1b). 1K(2)KZ1KLZ2L (1b) was also obtained
from the selective synthesis as foamy white solid aer prepar-
ative RP-HPLC (6.4 mg, 4.5%). Analytical RP-HPLC: tR ¼
2.570 min (A/D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm).
MS(ESI+): C40H71N11O9S2 calc./obs. 914.19/914.49 Da [M + H]
+.
L1LK(L2L)KLKZ2KKLZ1K (11a). L1LK(L2L)KLKZ2KKLZ1K (11a)
was obtained as foamy white solid aer preparative RP-HPLC
(37.3 mg, 14.7%). Analytical RP-HPLC: tR ¼ 2.910 min (A/D
100:0 to 0:100 in 10.00 min, l ¼ 214 nm). MS(ESI+):
C82H151N21O16S2 calc./obs. 1750.11/1750.11 Da [M].
L1LK(L2L)KLKZ1KKLZ2K (11b). L1LK(L2L)KLKZ1KKLZ2K
(11b) was obtained as foamy white solid aer preparative RP-
HPLC (11.5 mg, 4.5%). Analytical RP-HPLC: tR ¼ 3.090 min (A/
D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm). MS(ESI+):
C82H151N21O16S2 calc./obs. 1750.11/1750.11 Da [M].
K2LLK(K1LL)KLZ1KKLZ2 (13a). K2LLK(K1LL)KLZ1KKLZ2 (13a)
was obtained as foamy yellow solid aer preparative RP-HPLC
(12.7 mg, 5.0%). Analytical RP-HPLC: tR ¼ 3.080 min (A/D
100:0 to 0:100 in 10.00 min, l ¼ 214 nm). MS(ESI+):
C82H151N21O16S2 calc./obs. 1750.11/1750.11 Da [M].
K1LLK(K2LL)KLZ1KKLZ2 (13b). K1LLK(K2LL)KLZ1KKLZ2
(13b) was obtained as foamy white solid aer preparative RP-
HPLC (7.9 mg, 3.1%). Analytical RP-HPLC: tR ¼ 3.250 min (A/This journal is © The Royal Society of Chemistry 2017
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View Article OnlineD 100:0 to 0:100 in 10.00 min, l ¼ 214 nm). MS(ESI+):
C82H151N21O16S2 calc./obs. 1750.11/1750.11 Da [M].
K12LKK(K12LK)LLLZ21KLKZ12L (19). K12LKK(K12LK)
LLLZ21KLKZ12L (19) was obtained as foamy white solid aer
preparative RP-HPLC (7.9 mg, 2.7%). Analytical RP-HPLC: tR ¼
1.510 min (A/D 100:0 to 0:100 in 5.00 min, l ¼ 214 nm).
MS(ESI+): C94H174N24O18S2 calc./obs. 1991.29/1991.29 Da [M].
1KLLK(K2LL)KLLZ2KLKZ1K (26a). 1KLLK(K2LL)
KLLZ2KLKZ1K (26a) was obtained as foamy white solid aer
preparative RP-HPLC (5.8 mg, 2.6%). Analytical RP-HPLC: tR ¼
3.340 min (A/D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm).
MS(ESI+): C94H174N24O18S2 calc./obs. 1991.29/1991.30 Da [M].
1KLLK(K2LL)KLLZ1KLKZ2K (26b). 1KLLK(K2LL)
KLLZ1KLKZ2K (26b) was obtained as foamy white solid aer
preparative RP-HPLC (23.0 mg, 10.3%). Analytical RP-HPLC: tR
¼ 3.640 min (A/D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm).
MS(ESI+): C94H174N24O18S2 calc./obs. 1991.29/1991.30 Da [M].
2KLKK(K1LK)KLLZ1LLLZ2K (27a). 2KLKK(K1LK)
KLLZ1LLLZ2K (27a) was obtained as foamy white solid aer
preparative RP-HPLC (19.9 mg, 8.8%). Analytical RP-HPLC: tR ¼
3.140 min (A/D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm).
MS(ESI+): C94H174N24O18S2 calc./obs. 1991.29/1991.30 Da [M].
2KLKK(K1LK)KLLZ1LLLZ2K (27a). 2KLKK(K1LK)
KLLZ1LLLZ2K (27a) was also obtained from the selective
synthesis procedure as foamy white solid aer preparative RP-
HPLC (0.3 mg, 0.1%). Analytical RP-HPLC: tR ¼ 3.140 min (A/
D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm). MS(ESI+):
C94H174N24O18S2 calc./obs. 1991.29/1991.30 Da [M].
1KLKK(K2LK)KLLZ1LLLZ2K (27b). 1KLKK(K2LK)
KLLZ1LLLZ2K (27b) was obtained as foamy white solid aer
preparative RP-HPLC (13.2 mg, 5.9%). Analytical RP-HPLC: tR ¼
3.370 min (A/D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm).
MS(ESI+): C94H174N24O18S2 calc./obs. 1991.29/1991.30 Da [M].
1KLKK(K2LK)KLLZ1LLLZ2K (27b). 1KLKK(K2LK)
KLLZ1LLLZ2K (27b) was also obtained from the selective
synthesis procedure as foamy white solid aer preparative RP-
HPLC (0.2 mg, 0.09%). Analytical RP-HPLC: tR ¼ 3.370 min (A/
D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm). MS(ESI+):
C94H174N24O18S2 calc./obs. 1991.29/1991.30 Da [M].
2KLLK(K1LL)KLLZ1KKKZ2L (29a). 2KLLK(K1LL)
KLLZ1KKKZ2L (29a) was obtained as foamy white solid aer
preparative RP-HPLC (9.8 mg, 3.5%). Analytical RP-HPLC: tR ¼
3.280 min (A/D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm).
MS(ESI+): C94H174N24O18S2 calc./obs. 1991.29/1991.29 Da [M].
1KLLK(K2LL)KLLZ1KKKZ2L (29b). 1KLLK(K2LL)
KLLZ1KKKZ2L (29b) was obtained as foamy white solid aer
preparative RP-HPLC (27.7 mg, 10.1%). Analytical RP-HPLC: tR
¼ 3.570 min (A/D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm).
MS(ESI+): C94H174N24O18S2 calc./obs. 1991.29/1991.29 Da [M].
2KLKK(K1LK)KLLZ1LLKZ2K (36a). 2KLKK(K1LK)
KLLZ1LLKZ2K (36a) was obtained as foamy white solid aer
preparative RP-HPLC (11.2 mg, 4.0%). Analytical RP-HPLC: tR ¼
2.890 min (A/D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm).
MS(ESI+): C94H175N25O18S2 calc./obs. 2006.30/2006.30 Da [M].
1KLKK(K2LK)KLLZ1LLKZ2K (36b). 1KLKK(K2LK)
KLLZ1LLKZ2K (36b) was obtained as foamy white solid aer
preparative RP-HPLC (11.8 mg, 4.1%). Analytical RP-HPLC: tR ¼This journal is © The Royal Society of Chemistry 20172.970 min (A/D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm).
MS(ESI+): C94H175N25O18S2 calc./obs. 2006.30/2006.30 [M].
1KKKK(K2KK)KLLZ1LLLZ2K (56a). 1KKKK(K2KK)
KLLZ1LLLZ2K (56a) was obtained as foamy white solid aer
preparative RP-HPLC (10.8 mg, 4.3%). Analytical RP-HPLC: tR ¼
2.860 min (A/D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm).
MS(ESI+): C94H176N26O18S2 calc./obs. 2021.31/2021.31 Da [M].
2KKKK(K1KK)KLLZ2LLLZ1K (56b). 2KKKK(K1KK)
KLLZ2LLLZ1K (56b) was obtained as foamy white solid aer
preparative RP-HPLC (7.4 mg, 2.9%). Analytical RP-HPLC: tR ¼
3.360 min (A/D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm).
MS(ESI+): C94H176N26O18S2 calc./obs. 2021.31/2022.31 Da [M].
12KWKK(K12WK)KWWZ21WWWZ12K (59). 12KWKK(K12WK)
KWWZ21WWWZ12K (59) was obtained as a single isomer, as
foamy white solid aer preparative RP-HPLC (11.0 mg, 4.4%).
Analytical RP-HPLC: tR ¼ 1.600 min (A/D 100:0 to 0:100 in
5.00 min, l ¼ 214 nm). MS(ESI+): C129H167N31O18S2 calc./obs.
2502.25/2502.26 Da [M].
2BLBK(B1LB)BLLZ1LLLZ2B (60a). 2BLBK(B1LB)BLLZ1LLLZ2B
(60a) was obtained as foamy white solid aer preparative RP-
HPLC (7.6 mg, 3.2%). Analytical RP-HPLC: tR ¼ 2.840 min (A/
D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm). MS(ESI+):
C82H150N24O18S2 calc./obs. 1823.10/1824.10 Da [M].
2BLBK(B1LB)BLLZ2LLLZ1B (60b). 2BLBK(B1LB)BLLZ2LLLZ1B
(60b) was obtained as foamy white solid aer preparative RP-
HPLC (3.5 mg, 1.4%). Analytical RP-HPLC: tR ¼ 2.90 min (A/D
100:0 to 0:100 in 10.00 min, l ¼ 214 nm). MS(ESI+):
C82H150N24O18S2 calc./obs. 1823.10/1823.10 Da [M].
12RLRK(R21LR)RLLZ21LLLZ12R (61). 12RLRK(R21LR)
RLLZ21LLLZ12R (61) was obtained as foamy white solid, like
a mixture of two isomers, aer preparative RP-HPLC (9.5 mg,
3.9%). Analytical RP-HPLC: tR¼ 3.260min (A/D 100:0 to 0:100 in
10.00 min, l ¼ 214 nm). MS(ESI+): C94H174N36O18S2 calc./obs.
2159.52 Da [M] found 2160.52 [M + H]+, 2274.32 [M + TFA]+,
2388.31 [M + 2TFA]+, 2502.30 [M + 3TFA]+.Synthesis of bicyclic lipidated and fucosylated peptides
The bicyclic peptides 62a/b–65a/b were prepared as mixture of
isomers a and b using the SPPS procedure described above
starting with an additional Fmoc-Lys(Alloc)-OH building block
as the rst residue in the sequence.
Before the last Fmoc deprotection the Alloc group was
removed as described above, and the lysine side chain of the
rst residue was coupled with either decanoic acid or per-
acetylated a-L-fucosyl-acetic acid as follows: the acid (5 eq.),
HATU (4 eq.) and DIPEA (10 eq.) were dissolved in 4.5 mL of
NMP and 1.5 mL of DCM and added to the syringe. The mixture
was stirred overnight. The solvent was ltrated and the washing
step, NMP (2  6 mL), MeOH (2  6 mL) and DCM (2  6 mL),
was performed.
The two N-terminal Fmoc groups were then removed and the
two N-termini were chloroacetylated as described above. The
dendrimer was then cleaved from the resin, puried, and
cyclized in solution. For the fucose containing compounds the
acetyl groups were removed prior to HPLC purication as
follows: the cyclization solution was lyophilized, and the crudeChem. Sci., 2017, 8, 6784–6798 | 6793
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View Article Onlinebicyclic glycopeptide was dissolved and stirred 24 h in a mixture
of MeOH/H2O/NH3 (8 : 1 : 1). The MeOH was removed under
vacuum and the solution was lyophilized. Finally, the bicyclic
peptides were puried by preparative HPLC as above. Isomers
a and b could be separated in all cases.
2KLKK(K1LK)KLLZ1LLLZ2KK(C10) (62a).
2KLKK(K1LK)
KLLZ1LLLZ2KK(C10) (62a) was obtained as foamy white solid
aer preparative RP-HPLC (11.3 mg, 4.9%). Analytical RP-HPLC:
tR ¼ 4.080 min (A/D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm).
MS(ESI+): C110H204N26O20S2 calc./obs. 2273.52/2273.52 Da [M].
1KLKK(K2LK)KLLZ1LLLZ2KK(C10) (62b).
1KLKK(K2LK)
KLLZ1LLLZ2KK(C10) (62b) was obtained as foamy white solid
aer preparative RP-HPLC (8.5 mg, 3.6%). Analytical RP-HPLC:
tR ¼ 4.240 min (A/D 100:0 to 0:100 in 10.00 min, l ¼ 214 nm).
MS(ESI+): C110H204N26O20S2 calc./obs. 2273.52/2273.52 Da [M].
2K(1)KZ1KLZ2LK(cFuc) (63a). 2K(1)KZ1KLZ2LK(cFuc) (63a)
was obtained as a foamy white solid aer preparative RP-HPLC
(3.0 mg, 2.6%). Analytical RP-UHPLC: tR ¼ 1.47 min (A/D 100/
0 to 0/100 in 5.0 min, ow rate 1.2 mL min1, l ¼ 214 nm).
MS(ESI+) calc. for C54H95N13O15S2 1229.65 Da [M], found:
1230.66 [M + H]+, 615.83 [M + H]2+.
2K(1)KZ2KLZ1LK(cFuc) (63b). 2K(1)KZ2KLZ1LK(cFuc) (63b)
was obtained as a foamy white solid aer preparative RP-HPLC
(1.0 mg, 0.9%). Analytical RP-UHPLC: tR ¼ 1.48 min (A/D 100/
0 to 0/100 in 5.0 min, ow rate 1.2 mL min1, l ¼ 214 nm).
MS(ESI+) calc. for C54H95N13O15S2: 1229.65 Da [M], found:
1230.66 [M + H]+, 1252.66 [M + Na]+, 615.84 [M + H]2+.
1K(2)PaZ2yAz1K(cFuc) (64a). 1K(2)PaZ2yAz1K(cFuc) (64a) was
obtained as a foamy white solid aer preparative RP-HPLC
(0.6 mg, 0.5%). Analytical RP-UHPLC: tR ¼ 2.39 min (A/D 100/
0 to 0/100 in 7.5 min, ow rate 1.2 mL min1, l ¼ 214 nm).
MS(ESI+) calc. for C50H75N11O16S2 [M + H]
+: 1150.48, found:
1150.5, 597.22 [M + Na]2+.
2K(1)PaZ2yAz1K(cFuc) (64b). 2K(1)PaZ2yAz1K(cFuc) (64b) was
obtained as a foamy white solid aer preparative RP-HPLC
(1.7 mg, 1.5%). Analytical RP-UHPLC: tR ¼ 2.44 min (A/D 100/
0 to 0/100 in 7.5 min, ow rate 1.2 mL min1, l ¼ 214 nm).
MS(ESI+) calc. for C50H75N11O16S2 [M + H]
+: 1150.48, found:
1150.5, 575.75 [M + H]+, 1172.48 [M + Na]+.
2KLKK(K1LK)KLLZ1LLLZ2KK(cFuc) (65a). 2KLKK(K1LK)
KLLZ1LLLZ2KK(cFuc) (65a) was obtained as a foamy white solid
aer preparative RP-HPLC (2.3 mg, 1.2%). Analytical RP-
UHPLC: tR ¼ 2.35 min (A/D 100/0 to 0/100 in 10.0 min, ow
rate 1.2 mL min1, l ¼ 214 nm). MS(ESI+) calc. for
C108H198N26O24S2 2307.48/2307.48 Da [M].
1KLKK(K2LK)KLLZ1LLLZ2KK(cFuc) (65b). 1KLKK(K2LK)
KLLZ1LLLZ2KK(cFuc) (65b) was obtained as a foamy white solid
aer preparative RP-HPLC (2.0 mg, 1.0%). Analytical RP-
UHPLC: tR ¼ 2.63 min (A/D 100/0 to 0/100 in 10.0 min, ow
rate 1.2 mL min1, l ¼ 214 nm). MS(ESI+) calc. for
C108H198N26O24S2 2307.48/2307.48 Da [M].Antimicrobial activity by broth microdilution method
A colony of bacteria (Pseudomonas aeruginosa strain PA01 or
Bacillus subtilis strain BS168) from glycerol stock was grown in
LB medium overnight at 37 C and 180 rpm shaking. The6794 | Chem. Sci., 2017, 8, 6784–6798compounds were prepared as stock solutions of 8 mg mL1 in
sterilized MilliQ deionized water, added to the rst well of 96-
well sterile, polypropylene round bottommicrotiter plates (TPP,
untreated) and diluted serially by 1/2. The concentration of the
bacteria was quantied by measuring absorbance at 600 nm
and diluted to an OD600 of 0.022 in MH medium. The sample
solutions (150 mL) were mixed with 4 mL diluted bacterial
suspension with a nal inoculation of about 5  105 CFU. For
each test, two columns of the plate were kept for sterility control
(MH medium only), growth control (MH medium with bacterial
inoculum, no compound). The positive control, polymyxin B
(starting with a concentration of 64 mg mL1) in MH medium
with bacterial inoculums, was introduced in the two rst lines
of the plate. The plates were incubated at 37 C for 18 hours
under static conditions. 15 mL of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) (1 mg mL1 in steril-
ized MilliQ deionized water) were added to each well and the
plates were incubated for 20–30 minutes at room temperature.
The minimal inhibitory concentration (MIC) was dened as the
lowest concentration of the dendrimer that inhibits the visible
growth of the tested bacteria (yellow) with the unaided eye. For
broth microdilution assay, polymyxin B was used as references.
See also ESI Fig. S1–S3.†Pseudomonas aeruginosa biolm inhibition and dispersal
96-well sterile, U-bottomed polystyrene microtiter plates (TPP
Switzerland) were prepared by adding 200 mL of sterile deion-
ized water to the peripheral wells to decrease evaporation from
test wells. Aliquots of 180 mL of culture medium (0.25% (w/v)
nutrient broth no. 2, Oxoid) containing desired concentration
of the test compound were added to the internal wells.
Compound containing solutions were sterile ltered (pore size
0.22 mm) prior to addition to the wells. Inoculum of Pseudo-
monas aeruginosa strain PAO1 was prepared from 5 mL over-
night culture grown in LB broth overnight at 37 C and 180 rpm
shaking. Aliquots of 20 mL of overnight cultures, pre-washed in
0.25% (w/v) nutrient broth and normalized to an OD600 of 1,
were inoculated into the test wells. Plates were incubated in
a humid environment for 24–25 hours at 37 C under static
conditions. Wells were washed twice with 200 mL sterile
deionized water before staining with 200 mL 0.25% (w/v)
nutrient broth containing 0.5 mM WST-8 and 20 mM phena-
zine ethosulfate for 2.5–3 hours at 37 C under static conditions.
Aerwards, the well supernatants were transferred to a poly-
styrene at bottomed 96-well plate (TPP Switzerland) and the
absorbance was measured at 450 nm with a plate reader
(SpectraMax250 from Molecular Devices).
For biolm dispersal, biolm was formed as described above
but in the absence of compound for 24 hours. Wells were
washed twice with 200 mL sterile deionized water before adding
200 mL 0.25% (w/v) nutrient broth containing the desired
concentration of compound. Compound containing solutions
were sterile ltered (pore size 0.22 mm) prior to addition to the
wells. Aer another 24 hours of incubation at 37 C under static
conditions, the well supernatants were removed and the wells
were washed twice with 200 mL sterile deionized water. TheThis journal is © The Royal Society of Chemistry 2017
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View Article Onlinebiolm was stained with 200 mL of 0.25% (w/v) nutrient broth
containing 0.5 mMWST-8 and 20 mM phenazine ethosulfate for
2.5–3 hours at 37 C under static conditions. The resulting
absorbance was measured as in the biolm inhibition
experiment.
Hemolysis assay (MHC)
The approval for using the blood for hemolysis assay was given
by the Blutspendedienst SRK Bern AG (Switzerland). For this
experiment approval from an independent Ethics Committee
was not required. To determine the minimal hemolytic
concentration (MHC) stock solutions of 8 mg mL1 of the
peptide in H2O were prepared and 50 mL were diluted serially by
1/2 in 50 mL PBS (pH 7.4) in 96-well plate (Costar or Nunc,
polystyrene, untreated). Human red blood cells (hRBC) were
obtained by centrifugation of 1.5 mL of whole blood, from the
blood bank of Bern, at 3000 rpm for 15 minutes at 40 C. Plasma
was discarded and the pellet was re-suspended in a 15 mL
falcon tube up to 5 mL of PBS. The washing was repeated three
times and the remaining pellet was re-suspended in 10 mL of
PBS at a nal hRBC concentration of 5%. The hRBC suspension
(50 mL) was added to each well and the plate was incubated at
room temperature for 4 hours. Minimal hemolytic concentra-
tion (MHC) end points were determined by visual determina-
tion of the wells aer the incubation period. Controls on each
plate included a blank medium control (50 mL PBS + 50 mL of
hRBC suspension) and a hemolytic activity control (mQ-
deionized water 50 mL + 50 mL hRBC suspension).
Serum stability assay
Human serum was diluted in DMEM (1 : 4, v/v). Selected
peptide was diluted in Tris buﬀer to a concentration of 400 mM.
Aliquots of peptide solution (50 mL) were added to aliquots of
serum (50 mL) in sterile Eppendorf tubes, to reach a peptide
concentration of 200 mM during the assay. Samples were incu-
bated at 37 C under gentle stirring (350 rpm). Diﬀerent
samples (triplicates) were quenched at diﬀerent time points (0/
1/3/6/24 h) by precipitating serum proteins through the addi-
tion of (0.1 M) ZnSO4$7H2O/ACN (1 : 1) (0.1 M, 100 mL) and
cooling down in ice bath. Protein precipitates were pelleted
under centrifugation and the supernatants were sampled and
evaporated to dryness in a centrifugal evaporator. Samples were
re-suspended in a H2O/ACN (4 : 1, v/v) mixture and centrifuged
again to remove residual protein precipitate. Supernatants were
then sampled and analyzed by LC-MS. Experiment controls
included a precipitation control for each peptide, to test their
resistance to the protein precipitation conditions, and serum
blanks, to check reproducibility over diﬀerent serum batches.
Two peaks originating from DMEM, surviving the incubation in
serum and the protein precipitation conditions were used as
internal standard.
Membrane interaction experiment
Preparation of lipid vesicles. A thin lipid lm was prepared
by dissolving 25 mg of egg PC or egg PG in 1 mL MeOH/CHCl3
(1/1, v/v) and evaporating these solutions on a rotatoryThis journal is © The Royal Society of Chemistry 2017evaporator at room temperature and then under vacuum over-
night. The resulting lm was hydrated with 1 mL buﬀer (50 mM
carboxyuorescein, 10 mM Tris, 10 mM NaCl, pH 7.4) for
30 min, subjected to freeze–thaw cycles (6) and extrusion
(15) through a polycarbonate membrane (pore size 100 nm).
Extravesicular components were removed by gel ltration
(Sephadex G-50) with 10 mM Tris, 107 mM NaCl, pH 7.4.
Experiment. Egg PC or egg PG stock solutions (37.5 mL) were
diluted with a buﬀer (10 mM Tris buﬀer, 107 mM NaCl, pH 7.4)
and placed in a thermostated uorescence cuvette and gently
stirred. CF eﬄux was monitored at lem 517 nm as a function of
time aer addition of 20 mL of peptide in buﬀer with nal
concentrations of 1.0, 5.0, 7.5, 10, 15, 20 mg mL1 at time ¼ 50
seconds and 1.2% Triton X-100 (30 mL, 0.012% nal concen-
tration) at time ¼ 300 seconds.
TEM transmission electron microscopy
Exponential phase of Pseudomonas aeruginosa PAO1 were washed
with PBS and treated with 4 MIC of the corresponding
compound in M63 minimal medium. Each time, 1 mL of the
bacteria were centrifuged aer 15, 30 and 60 min at 12 000 rpm
for 3 min and xed overnight with 2.5% glutaraldehyde in 0.15 M
HEPES with an osmolarity of 670 mOsm and adjusted to a pH of
7.35. The next day, PAO1 were washed with 0.15 M HEPES three
times for 5 min, postxed with 1% OsO4 in 0.1 M Na-cacodylate-
buﬀer at 4 C for 1 h. Thereaer, bacteria cells were washed in
0.1 M Na-cacodylate-buﬀer three times for 5 min and dehydrated
in 70, 80, and 96% ethanol for 15 min each at room temperature.
Subsequently, they were immersed in 100% ethanol three times
for 10 min, in acetone two times for 10 min, and nally in
acetone–Epon (1 : 1) overnight at room temperature. The next day,
bacteria cells were embedded in Epon and hardened at 60 C for 5
days. Sections were produced with an ultramicrotome UC6, rst
semithin sections (1 mm) for light microscopy that were stained
with a solution of 0.5% toluidine blue O and then ultrathin
sections (70–80 nm) for electron microscopy. The sections,
mounted on single slot copper grids, were stained with uranyl
acetate and lead citrate with an ultrastainer. Sections were then
examined with a Tecnai Spirit transmission electron microscope
equipped with two digital cameras.
X-ray crystallography
LecB lectin was expressed, puried and dialyzed as previously
described.72 Co-crystallization of 63a/b with LecB lectin was
carried out by the sitting drop method. The lyophilized protein
was dissolved in water (5 mg mL1) in the presence of salts
(6 mM CaCl2 and MgCl2). The compounds were added to the
protein at a 20 : 1 molar excess, taking into account that the
biological unit of LecB is a homo-tetramer. Crystals were ob-
tained within ve days aer mixing 1.5 mL of LecB ligand-
complex with 1.5 mL of reservoir solution at 18 C. Primary
crystallization conditions were found in Crystal screens I/II
(Hampton Research, Laguna Niguel, CA, USA). Crystals of
highest diﬀraction were obtained from condition 0.2 M
ammonium acetate, 0.1 M sodium citrate tribasic dehydrate pH
5.6 and 30% w/v polyethylene glycol 4000, Crystal Screen I 9 inChem. Sci., 2017, 8, 6784–6798 | 6795
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View Article Onlinethe case of 63b. In the case of 63a the best condition was 0.2 M
sodium acetate trihydrate, 0.1 M Tris hydrochloride pH 8.5 and
30% w/v polyethylene glycol 4000, which is Crystal Screen I 22.
The structures were solved using the XDS,73 CCP4,74 the phenix75
program suite and the Coot76 graphical program. Pictures were
done using the PyMol soware.77
The crystallization of 64a succeeded with the soaking
method. The apo crystals were grown in the same way as
described above for the co-crystallization. Then diﬀerent
amounts of ligand were added. The best result was observed in
the Crystal Screen I condition 47 which contain 0.1 M sodium
acetate trihydrate pH 4.6 and 2.0 M ammonium sulfate. The
ligand was added in a volume of 2 mL which results in a nal
concentration factor of 12.3 for the ligand compared with the
protein concentration. All crystallization attempts with 64b and
65a/b either gave no crystals or well-resolved crystals in which
only the fucosylated linker gave observable electron density.Molecular dynamics
Molecular dynamics (MD) simulations were performed for
bicyclic peptide isomers 27a and 27b using GROMACS soware
version 2016.1 and the Gomos53a6 force eld.70 The starting
topology was built by adding the non-natural bonds to the
corresponding linear peptide and the initial coordinates were
generated using CORINA.71 A dodecahedral box was created
around the protein 1.0 nm from the edge of the protein and
lled with extended simple point charge water molecules.
Sodium and chloride ions were added to produce an electro-
neutral solution at a nal concentration of 0.15 M NaCl.
The energy wasminimized using a steepest gradientmethod to
remove any close contacts before the system was subjected to
a two-phase position-restrained MD equilibration procedure. The
system was rst allowed to evolve for 1.0 ns in a canonical NVT (N
is the number of particles, V the system volume, and T the
temperature) ensemble at 300 K before pressure coupling was
switched on and the system was equilibrated for an additional 50
ns in the NPT (P is the system pressure) ensemble at 1.0 bar.
This pre-equilibrated system was used as the starting point
for the simulated annealing molecular dynamics (SA-MD) run.
The system was heated to 450 K and high energy conformers
were sampled at 100, 150, 200, 250 and 300 ns. Each of the
conformers was the cooled from 450 K to 300 K over 50 ns and
allowed to evolve for an additional 200 ns. All bond lengths were
constrained to their equilibrium values by using the LINCS
algorithm. The neighbor list for the calculation of nonbonded
interactions was updated every ve time steps with a cutoﬀ of
1.0 nm with a step size of 2 fs. A twin range cutoﬀ of 1.0 nm was
used for both Coulomb and Lennard-Jones interactions. The
system was split into two groups, “Protein” and “Non-Protein”,
which were coupled separately to a temperature bath using the
V-rescale algorithm with a time constant of 0.1 ps while the
pressure coupling was conducted using an isotropic Parrinello–
Rahman barostat with a time constant of 2.0 ps.
The last 100 ns (150/ 250 ns) of each SA-MD run were used
in the subsequent analysis. To obtain a representative
conformer for each SA-MD run, the last 100 ns (10 001 frames)6796 | Chem. Sci., 2017, 8, 6784–6798of each run were clustered using an RMSD cut-oﬀ to 0.12 nm.
The large number of clusters combined with the very large
percentage of structures in the top cluster is an indication of the
stability of the one main conformer in each case (Table S6†).
The PyMol Molecular Graphics System, version 1.8
(Schro¨dinger, LLC), was used to create structural models.FTIR spectroscopy
Lyophilized bridged bicyclic peptides were dissolved at a nal
concentration of 6 mg mL1 in D2O based PBS (aq. 10 mM
phosphate, 150 mM NaCl, pH 7.4) in the presence of 0%, 50%,
and 90% of TFE. An aliquot of 15 mL of the peptide solution was
placed in a home-made transmission cell with two BaF2
windows and a Teon spacer of 100 mm. FTIR spectra were
acquired in transmission mode by the Varian 610-IR infrared
microscope coupled to the Varian 670-IR FTIR spectrometer and
equipped with a mercury cadmium telluride nitrogen-cooled
detector. The variable microscope aperture was adjusted to
200 mm diameter. Measurements were performed under the
following conditions: 2 cm1 of spectral resolution, 25 kHz of
scan speed, triangular apodization, and 2000 scan coadditions.
The peptide FTIR spectra were obtained aer subtraction of the
solvent spectra, collected under identical conditions, and were
normalized at the Amide I0 band area.
The Fourier-self-deconvolution (FSD) of the Amide I0 band
was performed by the Resolutions-Pro soware (Varian Aus-
tralia Pty Ltd.) by using an enhancement factor K¼ 2.4 and half-
bandwidth HW ¼ 13 cm1. Second derivative spectra were
calculated following the Savitsky–Golay method, aer a bino-
mial 11 points smoothing of the spectra by the GRAMS-32
soware (Galactic Industries, Salem, NH).Acknowledgements
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